Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate
External beam radiation therapy for prostate cancer, while effective, takes up to 9 weeks to
deliver on a Monday through Friday basis. Recent phase I/II studies from Seattle and Palo
Alto using stereotactic guidance to deliver high doses of radiation to the prostate over a 1
to 2 week period of time suggest that outcomes may be equal or superior to standard
approaches. These data, combined with markedly improved convenience for patients, make
radiosurgery (SBRT) for early-stage prostate cancer an enticing option. The goal of this
study is to offer a radiosurgical option to patients within the Sharp system under the
umbrella of an IRB-approved study.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
acute and late toxicity to the GU and GI systems
acute and late toxicity to the GU and GI systems based on the RTOG definitions will be compared to those of standard radiation therapy.
1 year follow-up
Geoffrey Weinstein, M.D.
United States: Institutional Review Board
|Sharp Memorial Hospital||San Diego, California 92123|